Platelets: The Physiology of Activation and Inhibition;Plaqueta: Fisiología de la activación y la inhibición

Revista Espanola de Cardiologia Suplementos

Volumn 13, Issue SUPPL.2, 2013, Pages 2-7

  López Farré, Antonio ^a   Macaya, Carlos ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Glycoprotein; Microparticle; Platelet; Platelet agonist

Indexed keywords

ANTITHROMBOCYTIC AGENT;

ARTICLE; THROMBOCYTE ACTIVATION;

EID: 84876789168     PISSN: 11313587     EISSN: 15792250     Source Type: Journal    
DOI: 10.1016/S1131-3587(13)70073-6     Document Type: Article

References (53)

1. Tirnaksiz E., Pamukcu B., Oflaz H., Nisanci Y. Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. J Thromb Thrombolysis 2009, 27:24-28.
2. Demirtunc R., Duman D., Basar M., Bilgi M., Teomete M., Garip T. The relationship between glycemic control and platelet activity in type 2diabetes mellitus. J Diabetes Complications 2009, 23:89-94.
3. Sato Y., Fujii S., Imagawa S., Ohmura K., Ohmura Y., Andoh Y., et al. Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers. Atheroscler Thromb 2007, 14:31-35.
4. López-Farré A., Macaya C. Efectos antitrombóticos y antinflamatorios de los ácidos grasos omega-3. Rev Esp Cardiol 2006, 6:31-37.
5. Bizzozero J. Ueber einen neuen Formbstandtheil des Blutes und dessen Rolle bei der Thrombose und der Blutgerinnung. Archiv Pathol Anat 1985, 90:261-332.
6. Senzel L., Gnatenko D.V., Bahou W.F. The plateletproteome. Curr Opin Hematol 2009, 16:329-333.
7. Yeaman M.R. Platelets in defense against bacterial pathogens. Cell Mol Life Sci 2010, 67:525-544.
8. Yeaman M.R., Norman D.C., Bayer A.S. Platelet microbicidal protein enhances antibiotic-induced killing of and postantibiotic effect in Staphylococcus aureus. Antimicrob Agents Chemother 1992, 36:1665-1670.
9. Kahner B.N., Shankar H., Murugappan S., Prasad G.L., Kunapuli S.P. Nucleotide receptor signaling in platelets. J Thromb Haemost 2006, 4:2317-2326.
10. Angiolillo D.J., Ferreiro J.L. Inhibición del receptor plaquetario P2Y12 de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terapéuticas actuales y perspectivas futuras. Rev Esp Cardiol 2010, 63:60-76.
11. Caen J., Wu Q. Hageman factor, platelets and polyphosphates: early history and recent connection. J Thromb Haemost 2010, 8:1670-1674.
12. Von Hundelshausen P., Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007, 100:27-40.
13. Andrews R.K., Gardiner E.E., Shen Y., Berndt M.C. Platelet interactions in thrombosis. IUBMB Life 2004, 56:13-18.
14. Siljander P.R., Munnix I.C., Smethurst P.A., Deckmyn H., Lindhout T., Ouwehand W.H., et al. Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. Blood 2004, 103:1333-1341.
15. Gawaz M., Langer H., May A.E. Platelets in inflammation and atherogenesis. J Clin Invest 2005, 115:3378-3384.
16. Chen C., Chai H., Wang X., Jiang J., Jamaluddin M.S., Liao D., et al. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood 2008, 112:3205-3216.
17. Kramer R.M., Roberts E.F., Um S.L., Börsch-Haubold A.G., Watson S.P., Fisher M.J., et al. p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J Biol Chem 1996, 271:27723-27729.
18. Tselepis A.D., Gerotziafas G., Andrikopoulos G., Anninos H., Vardas P. Mechanisms of platelet activation and modification of response to antiplatelet agents. Hellenic J Cardiol 2011, 52:128-140.
19. Léon C., Hechler B., Freund M., Eckly A., Vial C., Ohlmann P., et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptornull mice. J Clin Invest 1999, 104:1731-1737.
20. Paul B.Z., Jin J., Kunapuli S.P. Molecular mechanism of thromboxane A(2)-induced platelet aggregation Essential role for p2t(ac) and alpha(2a) receptors. J Biol Chem 1999, 274:29108-29114.
21. Shattil S.J. Signaling through platelet integrin alpha IIb beta 3: inside-out, outsidein, and sideways. Thromb Haemost 1999, 82:318-325.
22. Tomiyama Y., Tsubakio T., Piotrowicz R.S., Kurata Y., Loftus J.C., Kunicki T.J. The Arg-Gly- Asp (RGD) recognition site of platelet glycoprotein IIb-IIIa on nonactivated platelets is accessible to high-affinity macromolecules. Blood 1992, 79:2303-2312.
23. Angiolillo D.J., Capodanno D., Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010, 31:17-28.
24. Kahn M.L., Zheng Y.W., Huang W., Bigornia V., Zeng D., Moff S., et al. A dual thrombin receptor system for platelet activation. Nature 1998, 394:690-694.
25. Vu T.K., Hung D.T., Wheaton V.I., Coughlin S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991, 64:1057-1068.
26. Leger A.J., Jacques S.L., Badar J., Kaneider N.C., Derian C.K., Andrade-Gordon P., et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 2006, 113:1244-1254.
27. Kato Y., Kita Y., Hirasawa-Taniyama Y., Nishio M., Mihara K., Ito K., et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist FR171113, in the guinea pig. Eur J Pharmacol 2003, 473:163-169.
28. Radomski M.W., Palmer R.M., Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates F aggregation. Proc Natl Acad Sci F USA 1990, 87:5193-5197.
29. Bergandi L., Cordero M., Anselmino M., Ferraro G., Ravera L., Dalmasso P., et al. Altered nitric oxide/cGMP platelet signaling pathway in platelets from patients with acute coronary syndromes. Clin Res Cardiol 2010, 99:557-564.
30. López-Farré A., Riesco A., Digiuni E., Mosquera J.R., Caramelo C., De Miguel L.S., et al. Aspirin-stimulated nitric oxide production by neutrophils after acute myocardial ischemia in rabbits. Circulation 1996, 94:83-87.
31. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001, 88:756-762.
32. Beghetti M., Sparling C., Cox P.N., Stephens D., Adatia I. Inhaled NO inhibits platelet aggregation and elevates plasma but not intraplateletcGMP in healthy human volunteers. Am J Physiol Heart Circ Physiol 2003, 285:H637-H642.
33. López-Farré A., Caramelo C., Esteban A., Alberola M.L., Millás I., Montón M., et al. Effects of aspirin on platelet-neutrophil interactions Role of nitric oxide and endothelin-1. Circulation 1995, 91:2080-2088.
34. Grosser N., Schröder H. Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler Thromb Vasc Biol 2003, 23:1345-1351.
35. Aszódi A., Pfeifer A., Ahmad M., Glauner M., Zhou X.H., Ny L., et al. The vasodilatorstimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J 1999, 18:37-48.
36. Hauser W., Knobeloch K.P., Eigenthaler M., Gambaryan S., Krenn V., Geiger J., et al. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc Natl Acad Sci USA 1999, 96:8120-8125.
37. Santilli F., Vazzana N., Liani R., Guagnano M.T., Davì G. Platelet activation in obesity and metabolic syndrome. Obes Rev 2012, 13:27-42.
38. Rajendran S., Chirkov Y.Y. Platelet hyperaggregability: impaired responsiveness to nitric oxide (" platelet NO resistance") as a therapeutic target. Cardiovasc Drugs Ther 2008, 22:193-203.
39. Vizioli L., Muscari S., Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract 2009, 63:1509-1515.
40. Ault K.A., Rinder H.M., Mitchell J., Carmody M.B., Vary C.P., Hillman R.S. The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol 1992, 98:637-646.
41. Lakkis N., Dokainish H., Abuzahra M., Tsyboulev V., Jorgensen J., De Leon A.P., et al. Reticulated platelets in acute coronary syndrome: a marker of platelet activity. J Am Coll Cardiol 2004, 44:2091-2093.
42. Guthikonda S., Lev E.I., Patel R., DeLao T., Bergeron A.L., Dong J.F., et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007, 5:490-496.
43. Mateos-Cáceres P.J., Macaya C., Azcona L., Modrego J., Mahillo E., Bernardo E., et al. Different expression of proteins in platelets from aspirin-resistant and aspirinsensitive patients. Thromb Haemost 2010, 103:160-170.
44. Horstman L.L., Ahn Y.S. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol 1999, 30:111-142.
45. Flaumenhaft R. Formation and fate of platelet microparticles. Blood Cells Mol Dis 2006, 36:182-187.
46. López-Farré A.J., Zamorano-Leon J.J., Azcona L., Modrego J., Mateos-Cáceres P.J., González-Armengol J., et al. Proteomic changes related to "bewildered" circulating platelets in the acute coronary syndrome. Proteomics 2011, 11:3335-3348.
47. Mehta S.R., Bassand J.P., Chrolavicius S., Diaz R., Eikelboom J.W., et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010, 363:930-942. Current-Oasis 7 Investigators.
48. Wiviott S.D., Braunwald E., Angiolillo D.J., Meisel S., Dalby A.J., Verheugt F.W., et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel. in patients with diabetes mellitus in the trial to assess improvement in therapeutic. outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008, 118:1626-1636.
49. Montalescot G., Wiviott S.D., Braunwald E., Murphy S.A., Gibson C.M., McCabe C.H., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009, 373:723-731.
50. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
51. Harrington R.A., Stone G.N., McNulty S., White H.D., Lincoff A.M., Gibson M., et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009, 361:2318-2329.
52. Bhatt D.L., Lincoff A.M., Gibson C.M., Stone G.N., McNulty S., Montalescot G. Intravenous platelet blockade with cangrelol during PCI. N Engl J Med 2009, 361:2330-2341.
53. Leonordi S., Rao S.V., Harrington R.A., Bhett D.L., Gibson C.M., Roe M.T., et al. Rationale and design of the randomized double-blind trial testing. INTraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor versus clopidrogrel to evaluate torelability and efficacy in nonurgent percutaneous coronary interventions patients (INNOVATE-PCI). Am Heart J 2010, 160:65-72.